XXII Stock Overview
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
22nd Century Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$2.71 |
| 52 Week Low | US$0.82 |
| Beta | 1.84 |
| 1 Month Change | 20.59% |
| 3 Month Change | -15.27% |
| 1 Year Change | -45.59% |
| 3 Year Change | 19.77% |
| 5 Year Change | -59.34% |
| Change since IPO | -14.62% |
Recent News & Updates
Recent updates
Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?
Jan 13
22nd Century Group (NASDAQ:XXII) Has Debt But No Earnings; Should You Worry?
Sep 02Will 22nd Century Group (NASDAQ:XXII) Spend Its Cash Wisely?
May 10Is 22nd Century Group (NASDAQ:XXII) A Risky Investment?
Nov 23We Think 22nd Century Group (NYSEMKT:XXII) Can Afford To Drive Business Growth
Mar 23Introducing 22nd Century Group (NYSEMKT:XXII), The Stock That Zoomed 164% In The Last Year
Jan 27
Is 22nd Century Group (NYSEMKT:XXII) A Risky Investment?
Dec 01Shareholder Returns
| XXII | US Tobacco | US Market | |
|---|---|---|---|
| 7D | -8.3% | -4.9% | 2.8% |
| 1Y | -45.6% | -16.0% | -9.2% |
Return vs Industry: XXII underperformed the US Tobacco industry which returned -16% over the past year.
Return vs Market: XXII underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| XXII volatility | |
|---|---|
| XXII Average Weekly Movement | 12.1% |
| Tobacco Industry Average Movement | 13.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: XXII's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 76 | Jim Mish | https://www.xxiicentury.com |
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.
22nd Century Group, Inc. Fundamentals Summary
| XXII fundamental statistics | |
|---|---|
| Market Cap | US$238.98m |
| Earnings (TTM) | -US$47.48m |
| Revenue (TTM) | US$49.14m |
4.9x
P/S Ratio-5.0x
P/E RatioIs XXII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XXII income statement (TTM) | |
|---|---|
| Revenue | US$49.14m |
| Cost of Revenue | US$45.53m |
| Gross Profit | US$3.61m |
| Other Expenses | US$51.09m |
| Earnings | -US$47.48m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 7.35% |
| Net Profit Margin | -96.62% |
| Debt/Equity Ratio | 5.0% |
How did XXII perform over the long term?
See historical performance and comparison